<DOC>
	<DOCNO>NCT02143271</DOCNO>
	<brief_summary>This study design evaluate safety , pharmacokinetics pharmacodynamics single administration KHK7580 secondary hyperparathyroidism patient receive peritoneal dialysis .</brief_summary>
	<brief_title>Study KHK7580 Secondary Hyperparathyroidism Patients Receiving Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<criteria>Written inform consent Stable chronic renal disease patient receive peritoneal dialysis least 16 week prior screen intact parathyroid hormone value ≥ 240 pg/mL screening Corrected serum calcium ≥ 8.4 mg/dL screen Patients primary hyperparathyroidism Patients receive cinacalcet within 2 week prior screen Patients begin take change dose/dosing regimen active vitamin D/its analog , phosphate binder and/or calcium contain compound within 2 week prior screen Patients underwent parathyroidectomy and/or parathyroid intervention Patients uncontrolled hypertension and/or diabetes Patients severe heart disorder Patients severe hepatic disease Patients take investigational drug another clinical trial within 12 week prior screen Patients judge ineligible participate study investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Secondary Hyperparathyroidism Patients Receiving Peritoneal Dialysis</keyword>
</DOC>